In pediatric NF1 patients, pharmacological inhibition of MEK with selumetinib or PD0325901 has led to clinically significant improvements in muscular strength [74], supporting a MEK/ERK-dependent mechanism underlying Nf1-associated muscle metabolism. Here, MAP2K7 is linked to neurofibromatosis type 1.